Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
Executive Summary
As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005
You may also be interested in...
Genentech Tissue Product Sales Stall; Rituxan Driving Immunology
Sales growth has stalled for Genentech's tissue growth and repair products, with U.S. sales in the fourth quarter of 2007 nearly identical to third quarter totals. Compared to the fourth quarter of 2006, U.S. sales were down 5 percent
Genentech Tissue Product Sales Stall; Rituxan Driving Immunology
Sales growth has stalled for Genentech's tissue growth and repair products, with U.S. sales in the fourth quarter of 2007 nearly identical to third quarter totals. Compared to the fourth quarter of 2006, U.S. sales were down 5 percent
Genentech Girds For Competition From Generics And Big Pharma
Genentech will develop a defensive plan for each of its products in preparation for the potential introduction of follow-on biologics, Exec VP-Commercial Operations Ian Clark said during an investor update meeting March 17